Compare ConocoPhillips (COP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Moderna, Inc. — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: ConocoPhillips is far larger — about 2× Moderna, Inc.'s market cap, and ConocoPhillips pays a 2.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Moderna, Inc. for 59 Days on average.
| COP | MRNA | |
|---|---|---|
Market Cap | $161.21B | $78.65B |
Volume | 6,058,403 | 37,373,437 |
Sector | Energy | Health |
52-Week High | $141.22 | $203.46 |
52-Week Low | $85.66 | $22.36 |
Typical Hold Time | 79 Days | 59 Days |
Enterprise Value | $176.81B | $74.80B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.10, up 3.28% today, showing strong momentum with two consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends. Fundamentally, the company maintains solid profitability with 14.65% net income margin and reasonable valuation at 17.75 P/E ratio. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and UK operations.
Outlook remains positive with 75% analyst buy ratings and $154.75 consensus price target suggesting 15% upside. Key opportunities include energy market strength and strategic LNG expansion, while risks involve oil price volatility and geopolitical exposure in Middle East operations. The company's strong cash flow generation supports shareholder returns through dividends and buybacks.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
